HUP0303843A2 - CLyA-hemolizin alkalmazása proteinek exkretáltatására - Google Patents

CLyA-hemolizin alkalmazása proteinek exkretáltatására

Info

Publication number
HUP0303843A2
HUP0303843A2 HU0303843A HUP0303843A HUP0303843A2 HU P0303843 A2 HUP0303843 A2 HU P0303843A2 HU 0303843 A HU0303843 A HU 0303843A HU P0303843 A HUP0303843 A HU P0303843A HU P0303843 A2 HUP0303843 A2 HU P0303843A2
Authority
HU
Hungary
Prior art keywords
protein
export
proteins
clya
hemolysin
Prior art date
Application number
HU0303843A
Other languages
English (en)
Inventor
James E. Galen
Original Assignee
University Of Maryland, Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Maryland, Baltimore filed Critical University Of Maryland, Baltimore
Publication of HUP0303843A2 publication Critical patent/HUP0303843A2/hu
Publication of HUP0303843A3 publication Critical patent/HUP0303843A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • External Artificial Organs (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A találmány protein-exportrendszer alkalmazására vonatkozik. Atalálmány tárgyát hatásos eljárások és készítmények képezikrekombináns proteinek előállítására. A találmány szerinti expressziósrendszerben a kívánt proteint úgy expresszáltatják, hogy bakteriálissejtekbe a kívánt proteint kódoló szekvenciával fuzionáltatottexportproteint kódoló szekvenciát tartalmazó expressziós kazettáttartalmazó expressziós vektort jutattnak, az expreszziós kazettátexpresszáltatják, és ily módon az exportproteint és a kívánt proteinttartalmazó fúziós proteint kapnak, amely a tenyésztőközegbeexportálódik. Ó
HU0303843A 2000-11-22 2001-11-23 Use of clya hemolysin for excretion of proteins HUP0303843A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25251600P 2000-11-22 2000-11-22
PCT/US2001/044185 WO2002083890A2 (en) 2000-11-22 2001-11-23 Use of clya hemolysin for excretion of fusion proteins

Publications (2)

Publication Number Publication Date
HUP0303843A2 true HUP0303843A2 (hu) 2004-03-01
HUP0303843A3 HUP0303843A3 (en) 2010-01-28

Family

ID=22956340

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303843A HUP0303843A3 (en) 2000-11-22 2001-11-23 Use of clya hemolysin for excretion of proteins

Country Status (16)

Country Link
US (2) US7056700B2 (hu)
EP (1) EP1412502B1 (hu)
JP (1) JP3976685B2 (hu)
AT (1) ATE474926T1 (hu)
AU (1) AU2001297770B2 (hu)
CA (1) CA2430322A1 (hu)
CZ (1) CZ20031378A3 (hu)
DE (1) DE60142646D1 (hu)
ES (1) ES2349114T3 (hu)
HU (1) HUP0303843A3 (hu)
MX (1) MXPA03004562A (hu)
NO (1) NO20032286L (hu)
NZ (1) NZ525735A (hu)
PL (1) PL366122A1 (hu)
WO (1) WO2002083890A2 (hu)
ZA (1) ZA200303851B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10208653A1 (de) * 2002-02-28 2003-09-18 Medinnova Ges Med Innovationen Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CN101827943B (zh) 2007-05-22 2016-04-13 康乃尔研究基金会有限公司 蛋白质在细菌及其衍生小泡表面展示的组合物和方法及其用途
CN105950608B (zh) * 2007-05-22 2019-12-17 康乃尔研究基金会有限公司 蛋白质在细菌及其衍生小泡表面展示的组合物和方法及其用途
EP2294090B1 (en) 2008-06-03 2014-05-14 University of Maryland, Baltimore NON-HEMOLYTIC ClyA FOR EXCRETION OF PROTEINS
CA2733425A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
US20100042072A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20120034155A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
WO2013151706A2 (en) 2012-04-06 2013-10-10 Cornell University Subunit vaccine delivery platform for robust humoral and cellular immune responses
BR112016022447A2 (pt) * 2014-03-28 2017-10-10 Novozymes As ressolubilização de cristais de proteína a ph baixo
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MA40920A (fr) 2014-11-07 2017-09-12 Takeda Vaccines Inc Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
MY193736A (en) 2017-11-03 2022-10-27 Takeda Vaccines Inc Method for inactivating zika virus and for determining the completeness of inactivation
CN110747155A (zh) * 2019-11-12 2020-02-04 湖南大学 减毒重组工程菌及其制备方法、应用和肿瘤靶向药物
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) * 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4355117A (en) * 1980-10-08 1982-10-19 Nabisco Brands, Inc. Process for preparing agglomerated fibrous cellulose
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4665027A (en) * 1983-11-03 1987-05-12 Bio-Process Innovation, Inc. Immobilized cell reactor-separator with simultaneous product separation and methods for design and use thereof
US5387744A (en) * 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
KR890005273A (ko) * 1987-09-09 1989-05-13 이정오 2중 실관 반응기에 의한 구연산의 연속 생산방법
DE4239612A1 (de) * 1992-11-25 1994-05-26 Cultor Oy Bioreaktor mit immobilisierten, Milchsäure-produzierenden Bakterien und dessen Verwendung in Fermentationsverfahren
US5525504A (en) * 1993-04-30 1996-06-11 Merck Patent Gesellschaft Mit Beschrankter Haftung Cytolysin gene and gene product
WO1994028137A1 (en) * 1993-05-24 1994-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulator of contact-mediated hemolysin
US5512480A (en) * 1994-03-11 1996-04-30 Baxter International Inc. Flow-through bioreactor with grooves for cell retention
US5585266A (en) * 1995-10-05 1996-12-17 Plitt; Cheryl A. Immobilized cell bioreactor
US6413768B1 (en) * 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Also Published As

Publication number Publication date
US7056700B2 (en) 2006-06-06
ATE474926T1 (de) 2010-08-15
EP1412502B1 (en) 2010-07-21
US20060147461A1 (en) 2006-07-06
NO20032286D0 (no) 2003-05-21
NZ525735A (en) 2005-07-29
JP2004532634A (ja) 2004-10-28
EP1412502A2 (en) 2004-04-28
MXPA03004562A (es) 2003-09-10
DE60142646D1 (en) 2010-09-02
WO2002083890A2 (en) 2002-10-24
HUP0303843A3 (en) 2010-01-28
WO2002083890A3 (en) 2004-02-26
ZA200303851B (en) 2004-05-11
NO20032286L (no) 2003-07-07
CZ20031378A3 (cs) 2003-09-17
CA2430322A1 (en) 2002-10-24
AU2001297770B2 (en) 2007-04-05
JP3976685B2 (ja) 2007-09-19
US7459161B2 (en) 2008-12-02
US20020146430A1 (en) 2002-10-10
PL366122A1 (en) 2005-01-24
ES2349114T3 (es) 2010-12-28

Similar Documents

Publication Publication Date Title
HUP0303843A2 (hu) CLyA-hemolizin alkalmazása proteinek exkretáltatására
HUP0101136A2 (hu) Fehérjeexpresszió baculovírus-vektort alkalmazó expressziós rendszerben
BRPI0413002A (pt) genes de ciclo de célula de planta e métodos de uso
ATE414782T1 (de) Verfahren zur herstellung von polypeptiden in mutierten aspergillus zellen
HUP0301659A2 (hu) Kukorica cellulóz-szintetázok és alkalmazásuk
AU2590901A (en) Il-17 homologous polypeptides and therapeutic uses thereof
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
ATE278024T1 (de) Methode zur herstellung von rekombinanten zellen
JPS59501693A (ja) 組換えｄｎａ分子及びその製造方法
DE602004028724D1 (de) Verfahren zur herstellung sezernierter polypeptide
SI1675956T1 (sl) Minimalno zaporedje dna, ki deluje kot izolirni element kromatina in njegova uporaba pri ekspresiji proteinov
AU4940096A (en) Host cell expressing reduced levels of a metalloprotease and methods using the host cell in protein production
Barrows et al. Synchronized swarmers and sticky stalks: Caulobacter crescentus as a model for bacterial cell biology
DK1200561T3 (da) Rekombinant stabil celleklon, dens fremstilling og anvendelse
PT1025245E (pt) Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
HUP0401869A2 (hu) Aminopeptidáz
ATE337336T1 (de) Nukleinsäuren, die für stichodactylidae chromoproteine kodieren
CA2088068A1 (en) Protein structure of the plant toxin gelonin
HUP0203221A2 (hu) A lignin bioszintézisében résztvevő enzimeket kódoló gének és alkalmazásuk
Burgos et al. Functional analysis of the Mycoplasma genitalium MG312 protein reveals a specific requirement of the MG312 N-terminal domain for gliding motility
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
EP1678308A4 (en) EXPRESSION VECTOR FOR SECRETING AN ANTIBODY FRAGMENT FROM AN E. COLI SIGNAL SEQUENCE AND METHOD FOR THE SERIAL PRODUCTION OF THE ANTIBODY FRAGMENT
ATE469920T1 (de) Herstellung von rekombinanten igm in den per.c6 zellen
DE69941789D1 (de) In vivo-verfahren zur herstellung von proteinen, die nicht-konventionelle aminosäuren enthalten
AU5049100A (en) Phage-dependent super-production of biologically active protein and peptides

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees